Cero Therapeutics Holdings, INC. (CEROW) — SEC Filings

Q: What are the key financial highlights for Cero Therapeutics Holdings, INC.?

Key financial highlights for Cero Therapeutics Holdings, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Cero Therapeutics Holdings, INC.?

Key executives at Cero Therapeutics Holdings, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cero Therapeutics Holdings, INC. stock?

Risk factors for Cero Therapeutics Holdings, INC. (CEROW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cero Therapeutics Holdings, INC.?

Forward-looking statements and predictions from Cero Therapeutics Holdings, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cero Therapeutics Holdings, INC.. Recent 8-K filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trad

View Cero Therapeutics Holdings, INC. on SEC EDGAR

Overview

Cero Therapeutics Holdings, INC. (CEROW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 5, 2025: CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed an S-1 on December 5, 2025, primarily for the resale of up to 729,596,950 shares of common stock by Keystone Capital Partners, LLC. These shares represent potential future issuances under a new Common Stock Purchase Agreement dated November 26, 2025, an

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Cero Therapeutics Holdings, INC. is neutral.

Filing Type Overview

Cero Therapeutics Holdings, INC. (CEROW) has filed 32 8-K, 4 S-1, 2 DEF 14A, 4 10-Q, 1 10-K/A, 1 10-K, 2 S-1/A, 2 SC 13G, 1 10-Q/A, 1 SC 13G/A with the SEC between Nov 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

8-K Filing — 8-K · Dec 19, 2025
CERO S-1 Reveals Massive Potential Dilution from Keystone Equity Line — S-1 · Dec 5, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed an S-1 on December 5, 2025, primarily for the resale of up to 729,596,950 shares of common stock by Keystone Capi
8-K Filing — 8-K · Dec 2, 2025
CERO THERAPEUTICS Proposes Reverse Split, Dilutive Issuance, and Share Increase — DEF 14A · Nov 28, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) is convening a Special Meeting of Stockholders on December 19, 2025, to address critical strategic and financial propos
CERO Therapeutics Faces Delisting, Deepening Losses Amid Financing Rounds — 10-Q · Nov 19, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) reported no revenue for the three and nine months ended September 30, 2025, consistent with its pre-commercial stage. T
Cero Therapeutics Faces Delisting Notice — 8-K · Oct 30, 2025 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on October 30, 2025, reporting on events as of October 29, 2025. The filing indicates a notice of delisting or fai
Cero Therapeutics Files 8-K for Material Agreements — 8-K · Oct 16, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on October 16, 2025, reporting on events that occurred on October 14, 2025. The filing indicates an entry into a m
Cero Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · Oct 14, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on October 14, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and fi
Cero Therapeutics Holdings Inc. 8-K Filing — 8-K · Sep 22, 2025 Risk: low
Cero Therapeutics Holdings, Inc. reported on September 22, 2025, that its common stock and warrants are traded on the Nasdaq Capital Market under the symbols CE
Cero Therapeutics Holdings Files 8-K — 8-K · Sep 5, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The company, formerly known as Phoenix B
Cero Therapeutics Faces Delisting Concerns — 8-K · Sep 4, 2025 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, f
CERO Therapeutics Posts $10.5M Q2 Loss Amid Financing & Stock Splits — 10-Q · Aug 22, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The com
CERO THERAPEUTICS Files S-1 for Continuous Offering — S-1 · Jul 21, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed an S-1 registration statement on July 21, 2025, indicating its intent for a delayed or continuous public offering
Cero Therapeutics Files 8-K on Equity Sales — 8-K · Jul 18, 2025 Risk: medium
On July 18, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report detailing unregistered sales of equity securities. The company, formerly known as Phoenix
Cero Therapeutics Enters Material Definitive Agreement — 8-K · Jul 14, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. entered into a Material Definitive Agreement on July 11, 2025. The filing also includes financial statements and exhibits relat
Cero Therapeutics to Acquire Private Company — 8-K · Jul 8, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. announced on July 7, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of a pri
Cero Therapeutics Files 8-K on Key Agreements — 8-K · Jun 30, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on June 25, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and finan
Cero Therapeutics Files 8-K — 8-K · Jun 17, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on June 17, 2025, reporting other events and financial statements. The company, formerly known as Phoenix Biotech
Cero Therapeutics Faces Nasdaq Delisting Notice — 8-K · Jun 13, 2025 Risk: high
Cero Therapeutics Holdings, Inc. announced on June 11, 2025, that it received a notice from Nasdaq regarding its failure to meet continued listing requirements.
Cero Therapeutics Holdings Files 8-K — 8-K · Jun 11, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on June 11, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial sta
Cero Therapeutics Files 8-K on Equity Sales — 8-K · Jun 6, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on June 6, 2025, reporting unregistered sales of equity securities and other events. The filing details the compan
Cero Therapeutics Reports Board and Officer Changes — 8-K · Jun 2, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 30, 2025, reporting changes in its board of directors and executive officers, along with updates to compens
Cero Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes — 8-K · May 29, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 29, 2025, reporting on several key events. These include the departure of directors or certain officers, th
Cero Therapeutics Files Q1 2025 10-Q Report — 10-Q · May 15, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, formerly known as Phoenix Biotech Acq
Cero Therapeutics Holdings Files 8-K — 8-K · May 8, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on May 8, 2025, reporting on events as of May 7, 2025. The filing indicates a change in the company's structure or
Cero Therapeutics Holdings Files Proxy Statement — DEF 14A · May 7, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed its definitive proxy statement on May 7, 2025, for its annual meeting on May 29, 2025. The company, formerly known as Pho
Cero Therapeutics Files 10-K Amendment — 10-K/A · Apr 28, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an amendment (Amendment No. 1) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. This filing
Cero Therapeutics Files 8-K with Corporate Updates — 8-K · Apr 25, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on April 25, 2025, reporting events as of April 22, 2025. The filing indicates amendments to its Articles of Incor
Cero Therapeutics Files 8-K: Material Agreements & Equity Sales — 8-K · Apr 22, 2025 Risk: medium
On April 21, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement,
Cero Therapeutics Files 2024 Annual Report — 10-K · Apr 15, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Phoenix Biotech Acquisition
Cero Therapeutics Files 8-K Report — 8-K · Feb 12, 2025 Risk: medium
On February 12, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific
Cero Therapeutics Enters Material Definitive Agreement — 8-K · Feb 6, 2025 Risk: medium
On February 5, 2025, Cero Therapeutics Holdings, Inc. entered into a material definitive agreement. The company, formerly known as Phoenix Biotech Acquisition C
Cero Therapeutics Holdings Inc. Files S-1/A Amendment — S-1/A · Feb 5, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an S-1/A amendment on February 5, 2025, for its registration statement. The company, formerly known as Phoenix Biotech Ac
Cero Therapeutics Files 8-K for Other Events — 8-K · Jan 21, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on January 21, 2025, reporting an event that occurred on January 17, 2025. The filing is categorized under 'Other
Cero Therapeutics Reports Unregistered Equity Sales — 8-K · Jan 10, 2025 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on January 10, 2025, reporting unregistered sales of equity securities that occurred on January 6, 2025. The filin
Cero Therapeutics Holdings, Inc. Files 8-K — 8-K · Jan 7, 2025 Risk: low
On January 7, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates the company's former name was Phoenix Biotech Acquisition Corp.,
Cero Therapeutics Holdings Files 8-K — 8-K · Jan 6, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on January 6, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial s
Cero Therapeutics Files 8-K on Equity Sales — 8-K · Dec 31, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. reported on December 23, 2024, regarding unregistered sales of equity securities and other events. The company, formerly known
Cero Therapeutics Holdings Files S-1 Registration — S-1 · Dec 23, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an S-1 registration statement on December 20, 2024, to register securities. The company, formerly known as Phoenix Biotec
SC 13G Filing — SC 13G · Dec 13, 2024
Cero Therapeutics Appoints New CMO, CSO, and Directors — 8-K · Dec 6, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. announced on December 2, 2024, the appointment of Dr. Jonathan G. Y. Chen as Chief Medical Officer and Dr. David M. R. Hall as
Cero Therapeutics Files for IPO — S-1 · Nov 27, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an S-1 registration statement on November 26, 2024, for its initial public offering. The company, formerly known as Phoen
Cero Therapeutics Holdings Inc. Files S-1/A Amendment — S-1/A · Nov 25, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an S-1/A amendment on November 25, 2024, for its registration statement. The company, formerly known as Phoenix Biotech A
Cero Therapeutics Files 10-Q/A Amendment — 10-Q/A · Nov 20, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an amendment (10-Q/A) to its quarterly report for the period ending September 30, 2024. The company, formerly known as Ph
SC 13G/A Filing — SC 13G/A · Nov 20, 2024
Cero Therapeutics Files Q3 2024 Report — 10-Q · Nov 19, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as Phoenix Biotech Acquisition
Cero Therapeutics Holdings, Inc. Files 8-K — 8-K · Nov 18, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed an 8-K on November 18, 2024, reporting on events as of November 15, 2024. The filing indicates the company's former name
SC 13G Filing — SC 13G · Nov 14, 2024
Cero Therapeutics Files 8-K on Agreements and Shareholder Votes — 8-K · Nov 12, 2024 Risk: medium
Cero Therapeutics Holdings, Inc. filed an 8-K on November 12, 2024, reporting on events that occurred on November 8, 2024. The filing indicates the entry into a
Cero Therapeutics Faces Delisting Notice — 8-K · Nov 1, 2024 Risk: high
Cero Therapeutics Holdings, Inc. filed an 8-K on October 30, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company w

Risk Profile

Risk Assessment: Of CEROW's 45 recent filings, 9 were flagged as high-risk, 22 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cero Therapeutics Holdings, INC.'s most recent 10-Q filing (Nov 19, 2025):

Revenue: $0
Net Income: $-47,078,070
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $2,022,072
Operating Margin: N/A
Total Assets: $3,911,394
Total Debt: $8,454,556

Key Executives

Chris Ehrlich
Stephen M. Davis
Jeffrey A. Letalien
Jonathan G. Y. Chen
David M. R. Hall
Sarah E. Kelly

Industry Context

Cero Therapeutics Holdings, Inc. operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on significant funding rounds to finance research and development, clinical trials, and eventual commercialization. The success of biotech firms is heavily dependent on scientific innovation, regulatory approvals, and effective market penetration against established players and emerging competitors.

Top Tags

biotech (11) · filing (9) · corporate-action (8) · equity-sale (6) · Biotechnology (5) · material-agreement (5) · delisting (4) · Reverse Stock Split (3) · corporate-update (3) · 8-K (3)

Key Numbers

Shares of Common Stock: 729,596,950 — Maximum shares registered for resale by Keystone Capital Partners, LLC, representing significant potential dilution.
Aggregate Gross Proceeds: $25M — Maximum amount CERO THERAPEUTICS HOLDINGS, INC. may receive from Keystone under purchase agreements, not from resale.
Dilution Percentage: 80.89% — Percentage of fully-diluted Common Stock outstanding if all registered shares are issued, as of November 24, 2025.
Share Price: $0.113 — Last quoted bid price for CEROW on OTCQB as of December 4, 2025, indicating a low valuation.
Shares Outstanding: 172,373,412 — Fully-diluted Common Stock outstanding as of November 24, 2025, prior to the potential issuance of the registered shares.
Minimum reverse stock split ratio: 1-for-40 — Proposed minimum ratio for combining outstanding shares of common stock
Maximum reverse stock split ratio: 1-for-150 — Proposed maximum ratio for combining outstanding shares of common stock
Additional shares for 2024 Equity Incentive Plan: 32,000,000 — Proposed increase in shares available for issuance under the 2024 Plan
Shares outstanding on record date: 20,802,671 — Number of Common Stock shares entitled to vote as of November 14, 2025
Record Date: November 14, 2025 — Date for determining stockholders eligible to vote at the Special Meeting
Special Meeting Date: December 19, 2025 — Date the 2025 Special Meeting of Stockholders will be held
Revenue: $0 — For the three and nine months ended September 30, 2025, indicating pre-commercial stage.
Net Loss: $10.5M — For the three months ended September 30, 2025, reflecting high operating expenses.
Shares of Common Stock outstanding: 21,102,671 — As of November 19, 2025, after multiple reverse stock splits and financings.
Reverse Stock Split Ratio: 1-for-100 — Effective January 8, 2025, reducing outstanding shares.

Related Companies

CERO

Frequently Asked Questions

What are the latest SEC filings for Cero Therapeutics Holdings, INC. (CEROW)?

Cero Therapeutics Holdings, INC. has 50 recent SEC filings from Nov 2024 to Dec 2025, including 32 8-K, 4 S-1, 4 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CEROW filings?

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Cero Therapeutics Holdings, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cero Therapeutics Holdings, INC. (CEROW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cero Therapeutics Holdings, INC.?

Key financial highlights from Cero Therapeutics Holdings, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CEROW?

The investment thesis for CEROW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cero Therapeutics Holdings, INC.?

Key executives identified across Cero Therapeutics Holdings, INC.'s filings include Chris Ehrlich, Stephen M. Davis, Jeffrey A. Letalien, Jonathan G. Y. Chen, David M. R. Hall and 1 others.

What are the main risk factors for Cero Therapeutics Holdings, INC. stock?

Of CEROW's 45 assessed filings, 9 were flagged high-risk, 22 medium-risk, and 14 low-risk.

What are recent predictions and forward guidance from Cero Therapeutics Holdings, INC.?

Forward guidance and predictions for Cero Therapeutics Holdings, INC. are extracted from SEC filings as they are enriched.